ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
9.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 104 citations in OpenAlex.
- A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Trial
- Rational design of pyrazole-oxime hybrids as dual-targeting agents for glioma and breast cancer brain metastasis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Targeting MET and mTOR Synergistically Overcomes Adaptive Resistance in Glioblastoma.International journal of molecular sciences · 2026Article
- BUB1 and CDK4/6 Dual Inhibition Increases Radiation Sensitivity in Glioblastoma, Lung Cancer, and Triple-Negative Breast Cancer.Biomedicines · 2026Article
- Exploring the landscape of targetable alterations in patients with glioblastoma.Nature reviews. Clinical oncology · 2026Review
- Molecular modulators of cyclin-dependent kinase 4/6 inhibitor response in experimental glioma identified through genome-wide CRISPR-Cas9 screening.Neuro-oncology · 2026Article
- A new hope: Clinical advances in targeted therapies for pediatric diffuse midline glioma.Neuro-oncology advances · 2026Review
- Review
- Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy.Cancer research · 2026Review
- Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma.Neuro-oncology · 2026Article
- Molecular docking and dynamics reveal novel CDK6 inhibitors for targeted glioblastoma therapy.Scientific reports · 2026Article
- Multiple patient-derived glioblastoma models reveal synthetic lethality through concurrent PI3K and CDK4/6 inhibition by blocking trans-active cooperation.Neuro-oncology · 2026Article
- Integration of MRI radiomics with immune profiling to predict response to CDK6 inhibitors in high-grade glioma.Frontiers in immunology · 2026Observational
- BNIP3-mTOR Signaling Mediates Resistance to MET Inhibition in Glioblastoma.bioRxiv : the preprint server for biology · 2025Article
- Abemaciclib impairs glioblastoma sphere formation by targeting the GSK3β-mediated transcriptional regulation of CD44 and TCF7L2.Cancer gene therapy · 2025Article
- Phenotypic variations in glioma stem cells: regulatory mechanisms and implications for therapeutic strategies.Journal of translational medicine · 2025Review
- A novel 5-protein kinase risk signature for predicting glioma prognosis and immunotherapy responsiveness.Scientific reports · 2025Article
- Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma.bioRxiv : the preprint server for biology · 2025Article
- Chemical Probes for Studying the Eukaryotic Translation Initiation Factor 4E (eIF4E)-Regulated Translatome in Cancer.ACS pharmacology & translational science · 2025Review
- Targeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and chemoradiation.bioRxiv : the preprint server for biology · 2025Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Inan OlmezDepartment of Neurology, University of Virginia, Charlottesville, Virginia.
Breanna BrennemanDepartment of Neurology, University of Virginia, Charlottesville, Virginia.
Aizhen XiaoDepartment of Neurology, University of Virginia, Charlottesville, Virginia.
Vlad SerbuleaDepartment of Pharmacology, University of Virginia, Charlottesville, Virginia.
Mouadh BenamarDepartment of Radiation Oncology, Biochemistry, and Molecular Genetics, University of Virginia, Charlottesville, Virginia.
Ying ZhangDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia.
Laryssa ManigatDepartment of Neurology, University of Virginia, Charlottesville, Virginia.
Tarek AbbasDepartment of Radiation Oncology, Biochemistry, and Molecular Genetics, University of Virginia, Charlottesville, Virginia.
Jeongwu LeeDepartment of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Ichiro NakanoDepartment of Neurosurgery, University of Alabama, Birmingham, Alabama.
Jakub GodlewskiDepartment of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts.
Agnieszka BroniszDepartment of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts.
Roger AbounaderDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia.
Norbert LeitingerDepartment of Pharmacology, University of Virginia, Charlottesville, Virginia.
Benjamin PurowDepartment of Neurology, University of Virginia, Charlottesville, Virginia. bwp5g@virginia.edu.
University of Virginia · USBrigham and Women's Hospital · USCleveland Clinic Lerner College of Medicine · USUniversity of Alabama at Birmingham · US
Funding
Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1MRole of Pannexins in Vascular Smooth Muscle CellsP01HL120840 · NHLBI · UNIVERSITY OF VIRGINIA · PI LEITINGER, NORBERT · 2014 to 2023
$24.0MCancer Research Training Program: From Molecular Mechanisms to Therapeutic StrategiesT32CA009109 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Andrew Carl Dudley, Melanie R Rutkowski · 1985 to 2026
$13.9MTRAINING IN THE PHARMACOLOGICAL SCIENCEST32GM007055 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI LYNCH, KEVIN R. · 1985 to 2022
$7.2MReceptor Tyrosine Kinase/PTEN Interactions in GliomasR01NS045209 · NINDS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI ABOUNADER, ROGER · 2003 to 2017
$4.1MNovel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasisR01CA189524 · NCI · UNIVERSITY OF VIRGINIA · PI PUROW, BENJAMIN W. · 2014 to 2018
$2.5MMicroRNA128 Regulation of Polycomb Repressor Complexes1 and 2 in GlioblastomaR01CA176203 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GODLEWSKI, JAKUB · 2014 to 2018
$1.8MTargeting diacylglycerol kinases in glioblastomaR01CA180699 · NCI · UNIVERSITY OF VIRGINIA · PI PUROW, BENJAMIN W. · 2014 to 2017
$1.6MRole of Dab2 in Fatty Liver DiseaseR01DK096076 · NIDDK · UNIVERSITY OF VIRGINIA · PI LEITINGER, NORBERT · 2013 to 2016
$1.4MThe Role of Oxidized Phospholipids in Macrophage Bioenergetics and InflammationF31DK108553 · NIDDK · UNIVERSITY OF VIRGINIA · PI SERBULEA, VLAD · 2016 to 2017
$60kNCI NIH HHS P30 CA044579NCI NIH HHS R01 CA176203NCI NIH HHS R01 CA180699NCI NIH HHS R01 CA189524NCI NIH HHS T32 CA009109NHLBI NIH HHS P01 HL120840NIDDK NIH HHS F31 DK108553NIDDK NIH HHS R01 DK096076NIGMS NIH HHS T32 GM007055NINDS NIH HHS R01 NS045209
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic AgentsApoptosisCaspase 3Caspase 7Cell Cycle CheckpointsCell Line, TumorCell ProliferationCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Disease Models, AnimalDisease ProgressionDrug SynergismEverolimusFemaleGlioblastomaAntineoplastic AgentsCaspase 3Caspase 7Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6EverolimuspalbociclibPiperazinesProtein Kinase InhibitorsPyridinesTOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.